ARGX ArGEN-X SE

argenx to Present at Upcoming Investor Conferences

argenx to Present at Upcoming Investor Conferences

November 26, 2024



Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in December.

  • Citi’s 2024 Global Healthcare Conference. Fireside chat on Tuesday, December 3 at 1:45 p.m. ET in Miami, FL.



  • 7th Annual Evercore I&I HealthCONx Conference. Fireside chat on Wednesday, December 4 at 1:45 p.m. ET in Coral Gables, FL.



  • Piper Sandler’s 35th Annual Healthcare Conference. Fireside chat on Thursday, December 5 at 9:00 a.m. ET in New York, NY.



Additional information regarding these events will be available on the Investors section of the argenx website at .

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker, globally in the U.S., Japan, Israel, the EU, the UK, China and Canada. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit and follow us on , , , , and .

For further information, please contact:

Media:

Ben Petok

Investors:

Alexandra Roy (US)

Lynn Elton (EU)



EN
26/11/2024

Underlying

ARGXArGEN-X SE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ArGEN-X SE

Hilde Van Boxstael ... (+3)
  • Hilde Van Boxstael
  • Thomas Vranken
  • Wim Lewi
AALB AALBERTS N.V.
ARGX ARGEN-X SE
HYL HYLORIS PHARMACEUTICALS
12/27/24 December 27, 2024 1 EN
Thomas Vranken
  • Thomas Vranken
ARGX ARGEN-X SE

argenx FIRST LOOK: CIDP approvals now include Japan

argenx announced the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the application for Vyvdura (SC efgartigimod) in adults with CIDP. Following gMG and ITP, CIDP represents the third indication for Vyvgart/Vyvdura in the country, and obtained self-administration in this geography as well. We reiterate our € 615 TP and Accumulate rating.

12/27/24 December 27, 2024 1 EN
 PRESS RELEASE
Free
ARGX ARGEN-X SE

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronid...

argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) in Japan for Adults with Chronic Inflammatory Demyelinating Polyneuropathy VYVDURA® now approved for at-home self-injection in Japan for both generalized myasthenia gravis and CIDP argenx's VYVGART® and VYVDURA portfolio approved in Japan for three indications – first country globally with access across three indications December 27, 2024, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from sever...

December 27, 2024 1 EN
Free Trial
ARGX ARGEN-X SE

Argen X SE: 1 director

A director at Argen X SE sold 9,950 shares at 585.000EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sho...

12/18/24 December 18, 2024 1 EN
 PRESS RELEASE
Free
ARGX ARGEN-X SE

argenx to Present at Upcoming Investor Conferences

argenx to Present at Upcoming Investor Conferences November 26, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that members of the management team will participate in the following upcoming investor conferences in December. Citi’s 2024 Global Healthcare Conference. Fireside chat on Tuesday, December 3 at 1:45 p.m. ET in Miami, FL. 7th Annual Evercore I&I HealthCONx Conference. Fireside chat on Wednesday, December 4 at 1:45 p.m. ET in Coral Ga...

November 26, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch